Market News AIOpen the app

Scholar Rock celebrates a big milestone with its first treatment for spinal muscular atrophy.

ResultsRead the original at benzinga.com
Good for SRRK

Scholar Rock received FDA approval for ISEMBYLD and is beginning U.S. commercial shipments, advancing its first-in-class product into the market.

SRRK · Scholar Rock Holding Corporation

AI read · Good for SRRK

The AI's read

Scholar Rock won FDA approval for ISEMBYLD, the first muscle-targeted SMA therapy showing motor improvement. The approval clears U.S. marketing and starts commercial shipments, boosting the company's product story.

Get alerts for SRRK

Follow Scholar Rock Holding Corporation (SRRK) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for SRRK
Free on the App Store and Google Play, or on the web.